Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8596 to 8610 of 8944 results

  1. Nivolumab + Brentuximab vedotin for Hodgkin lymphoma [ID6691]

    In development Reference number: GID-TA11909 Expected publication date: TBC

  2. Nivolumab in combination for untreated advanced classical Hodgkin lymphoma in people 12 years and over [ID6690]

    In development Reference number: GID-TA11908 Expected publication date: TBC

  3. Resminostat for maintenance treatment of advanced mycosis fungoides or Sezary syndrome [ID6478]

    In development Reference number: GID-TA11606 Expected publication date: TBC

  4. Empagliflozin for preventing cardiovascular events after acute myocardial infarction [ID6240]

    Discontinued Reference number: GID-TA11265

  5. Atezolizumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6148]

    Discontinued Reference number: GID-TA11074

  6. Xevinapant with platinum-based chemotherapy and radiotherapy for untreated locally advanced squamous cell head and neck cancer [ID6199]

    Discontinued Reference number: GID-TA11166

  7. Domvanalimab with zimberelimab for untreated unresectable advanced gastric, gastro-oesophageal junction or oesophageal cancer [ID6606]

    In development Reference number: GID-TA11801 Expected publication date: TBC

  8. Hidden spine fractures could be spotted earlier after NICE recommendation

    NICE is recommending that quick spine checks are added to routine bone scans to help spot hidden fractures earlier and prevent serious complications.

  9. Improving outcomes in urological cancers (CSG2)

    NICE has retired this cancer service guideline because the recommendations are no longer being kept up to date and may no longer reflect best practice.

  10. Improving supportive and palliative care for adults with cancer (CSG4)

    NICE has retired this cancer service guideline because the recommendations are no longer being kept up to date and may no longer reflect best practice.

  11. Improving outcomes in breast cancer (CSG1)

    NICE has retired this cancer service guideline because the recommendations are no longer being kept up to date and may no longer reflect best practice.

  12. Digital platforms recommended to help people manage their asthma

    People with asthma could benefit from digital tools on their phones or tablets to help them better manage their condition, states our draft guidance published today.

  13. New sepsis guideline targets faster, tailored treatments to benefit patients

    Patients aged 16 or over with suspected sepsis will receive more tailored treatment under updated NICE guidance published today.

  14. New age-based blood test thresholds recommended by NICE will help GPs catch ovarian cancer earlier

    More women with ovarian cancer could be diagnosed earlier under proposed new NICE guidance that replaces a one-size-fits-all blood test threshold with personalised, age-based criteria.

  15. NICE recommends new treatment option for highly active multiple sclerosis

    Thousands of people living with a form of multiple sclerosis (MS) will benefit from greater treatment choice, following new guidance from NICE.